Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

June 13, 2019

Advicenne (Euronext: ADVIC – FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan diseases, today announced the presentation of three posters at the 2019 conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in New Orleans (United States). ISPOR is an international organization that brings together experts and professionals in health economics and research.